Quoin Pharmaceuticals Stock (NASDAQ:QNRX)

Forecast Ownership Financials Chart

Previous Close

$4.62

52W Range

$4.10 - $41.80

50D Avg

$5.46

200D Avg

$9.40

Market Cap

$9.34M

Avg Vol (3M)

$99.58K

Beta

1.68

Div Yield

QNRX Company Profile

Quoin Pharmaceuticals, Ltd. operates as a specialized pharmaceutical firm, concentrating its efforts on devising therapeutic solutions for rare and orphan medical conditions. Its flagship offering, QRX003, is a topical lotion specifically formulated to address Netherton Syndrome. Furthermore, the company is advancing QRX004 for the management of dystrophic epidermolysis bullosa, alongside QRX006, a prospective therapy for an additional rare dermatological ailment. The organization maintains its operational base in Ashburn, Virginia.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Yes

Country

Employees

IPO Date

Aug 01, 2016

Website

QNRX Performance

QNRX Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	-	-
Operating Income	-	$-9.53M	$-9.38M
Net Income	$-15.80B	$-8.96M	$-8.69M
EBITDA	-	$-9.43M	$-9.27M
Basic EPS	$-14.80K	$-66.85	$-337.47
Diluted EPS	$-14.80K	$-66.85	$-337.47

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q4 23Mar 14, 24 | 8:30 AM

Q3 23Nov 09, 23 | 8:30 AM

Q2 23Aug 07, 23 | 8:30 AM

Peer Comparison

Ticker	Company
RADX	Radiopharm Theranostics Limited
VIVS	VivoSim Labs, Inc.
XTLB	XTL Biopharmaceuticals Ltd.
PLRZ	Polyrizon Ltd.
PMCB	PharmaCyte Biotech, Inc.
VYNE	VYNE Therapeutics Inc.
KTTA	Pasithea Therapeutics Corp.
TCRT	Alaunos Therapeutics, Inc.
CYCN	Cyclerion Therapeutics, Inc.